FDA Approves New Non-Muscle Invasive Bladder Cancer Treatment
This article represents the opinions, thoughts, and experiences of the author; none of this content has been paid for by any advertiser. The BladderCancer.net team does not recommend or endorse any products or treatments discussed herein. Learn more about how we maintain editorial integrity here.
- FDA approves pembrolizumab for BCG-unresponsive, high-risk non-muscle invasive bladder cancer. FDA.gov. Available at https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-pembrolizumab-bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer. Accessed 1/10/20.
- Mulcahy N. FDA Approves Pembrolizumab for High-Risk Bladder Cancer. Medscape. Available at https://www.medscape.com/viewarticle/923568?nlid=133404_3901&src=wnl_newsalrt_200108_MSCPEDIT&uac=285690FR&impID=2237632&faf=1. Accessed 1/11/20.
- D’Onofrio K. FDA Approves First New Bladder Cancer Treatment in 20 Years. Docwire News. Available athttps://www.docwirenews.com/docwire-pick/hem-onc-picks/fda-approves-first-new-bladder-cancer-treatment-in-20-years/. Accessed 1/10/20.
- Development History of Keytruda (pembrolizumab) Creative Biolabs. Available at https://www.creativebiolabs.net/blog/development-history-of-keytruda-pembrolizumab/. Accessed 1/11/20.